Medpage Today on MSN1d
GLP-1 Agents and Suicide: Making Sense of 2024's Mixed Data
Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...
Anavex Life Sciences: Jumping In On Time Ahead Of An Early Alzheimer's Decision
Anavex Life Sciences' ANAVEX 2-73 shows promise in treating Alzheimer's, with strong efficacy in slowing cognitive and ...
JD Supra2d
EMA’s CHMP Recommends Approval of Six New Biosimilars
The European Medicines Agency’s (EMA) Committee for Medicinal Use Products (CHMP) recently recommended approval of six new biosimilars.
News Medical on MSN1d
Faricimab lacks proof of added benefit over comparator therapies for macular edema
Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema ...
AstraZeneca Withdraws Lung Cancer Drug Application in EU
The latest announcement is out from AstraZeneca ( (AZN) ).
The Wall Street Journal on MSN13d
GSK’s Cancer Drug Jemperli Moves a Step Closer to European Marketing Permission
In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
European agency endorses approval of Biocon Biologics’ biosimilar Ustekinumab
BENGALURU: Biocon Biologics, a biosimilars company and subsidiary of Biocon, has announced that the European Medicines Agency ...
Danish agency seeks probe as Ozempic study shows link to vision loss
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...
Anavex price target raised to $42 from $40 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Anavex (AVXL) to $42 from $40 and keeps a Buy rating on the shares ...
AstraZeneca withdraws application for lung cancer drug in EU
AstraZeneca has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its ...